Tactile Medical targets $50M-$52M adjusted EBITDA in 2026 while maintaining $360M-$366M revenue outlook

Earnings Call Insights: Tactile Systems Technology, Inc. (TCMD) Q3 2026

Management View

• "We delivered total revenue of $91.9 million in Q3, led by a 13% year-over-year growth in lymphedema, marking our fifth consecutive quarter of above-market double-digit growth." (CEO, President & Director Sheri Dodd)

• "Airway clearance revenue was $10 million, down year-over-year as anticipated due to the onetime DME inventory transition associated with the launch of our next-generation AffloVest system." (CEO, President & Director Dodd)

• "Based on our year-to-date performance and our expectations for the fourth quarter, we are maintaining our full year 2026 revenue guidance of $360 million to $366 million and raising our adjusted EBITDA guidance to $50 million to $52 million." (CEO, President & Director Dodd)

• "Third quarter operating expenses increased $6.9 million or 12.7% to $60.9 million." (Chief Financial Officer Elaine Birkemeyer)

• "As announced today, Steve Kiewiet, is joining Tactile Medical as Chief Operating Officer." (CEO, President & Director Dodd)

Outlook

• "We are maintaining our full year 2026 revenue guidance of $360 million to $366 million." (CEO, President & Director Dodd)

• "We are raising our full year 2026 EBITDA guidance to $50 million to $52 million." (Chief Financial Officer Birkemeyer)

• "In airway clearance, we now expect full year revenue to decline in the mid- to high single digits compared with our prior expectation of approximately flat." (Chief Financial Officer Birkemeyer)

• "For the fourth quarter, we expect meaningful sequential growth with a moderation in year-over-year growth compared to recent quarters as we lap a particularly strong fourth quarter of 2025." (Chief Financial Officer Birkemeyer)

• "For modeling purposes, we expect the following for the full year: GAAP gross margin of approximately 76.5%, GAAP operating expense growth of 10% to 12%, net interest income of approximately $2.4 million, an effective tax rate of approximately 28% and fully diluted weighted average shares outstanding of approximately 23 million." (Chief Financial Officer Birkemeyer)

Financial Results

• "Net income was $7.2 million or $0.31 per diluted share." (Chief Financial Officer Birkemeyer)

• "Adjusted EBITDA was $14.3 million." (Chief Financial Officer Birkemeyer)

• "On the balance sheet, we ended the quarter with $75.1 million in cash and no outstanding borrowings." (Chief Financial Officer Birkemeyer)

• "During the third quarter, we generated $12 million in operating cash flow, which more than funded approximately $6.2 million in share repurchases." (Chief Financial Officer Birkemeyer)

• "Gross margin expanded to 76.7% of revenue." (Chief Financial Officer Birkemeyer)

Q&A

• Ryan Zimmerman, BTIG: asked whether lymphedema could slow and how management is thinking about 2027 puts/takes, including airway normalization; CEO Dodd: "We don't see any reason why there should be a slowdown" and added, "we're not going to be putting any specific guides on 2027," while also saying on AffloVest inventory timing, "We are going to see a sequential growth from Q3 to Q4. It's going to be a bit more moderated than what we had talked about in Q2."

• Ryan Zimmerman, BTIG: asked for quantitative considerations for Flexitouch Pro on price/margins; CEO Dodd: "Flexitouch Pro will fall as an EO652" and "gross margins will be in the ZIP code of our current products."

• Kyle Edward Winborne, Piper Sandler: asked how management is thinking about P&L leverage in 2027 while continuing to invest; CEO Dodd: "we have committed to operating leverage" and also cautioned, "there isn't just a sudden hockey stick that happens because now we will have the Flexitouch Pro and the 3D Scanner."

• Kyle Edward Winborne, Piper Sandler: asked to quantify commercial payer changes for head and neck and timing of revenue contribution; CEO Dodd: "we're not going to quantify or kind of call out the specific payers" and said, "it won't be a hockey stick either."

• Brandon Vazquez, William Blair: asked why AffloVest inventory rebuild is taking longer and Tactile’s confidence around the trough; CEO Dodd: "we are seeing that pace of burning through the inventory being a little bit slower than we had forecasted" and emphasized, "there's no change in the underlying patient demand, the therapy effectiveness or competition."

• Brandon Vazquez, William Blair: asked about the drivers and usefulness of the “referring clinics grew more than 10% year-to-date” metric; CEO Dodd: "we thought it would be good to put a little more quantification around what that rep productivity is actually really looking like" and tied it to "more feet on the street and better tools."

• Benjamin Haynor, Lake Street: asked what non-inventory DMEs are seeing with Gen 6 AffloVest and whether that can offset inventory drag; CEO Dodd: "what we're hearing is really strong feedback" but added, "we just can't overcome the excess -- the slowdown in the excess inventory burn with performance in the other DMEs."

• Benjamin Haynor, Lake Street: asked about 2027 field sales force expectations and LymphaTech monetization approach; CEO Dodd: "nothing dramatic is going to happen here" on sales force sizing and on LymphaTech monetization, "We are still taking a look at that full business model" and noted "moving on to actually seeing full year commercialization, which will be seen later in '28 and '29."

Sentiment Analysis

• Analyst sentiment was slightly positive overall, with supportive framing on profitability and forward growth potential, including Ryan Zimmerman, BTIG: "Elaine, congrats, the profitability" and a focus on whether lymphedema can “accelerate” into 2027.

• Management sentiment was slightly positive, pairing confidence in the core lymphedema trajectory with repeated tempering on timing, including CEO Dodd: "We don't see any reason why there should be a slowdown" and "we're not going to be putting any specific guides on 2027," plus repeated caution that new initiatives are not expected to be immediate "hockey stick" contributors.

• Compared with Q2, management language shifted toward more explicit caution on airway clearance normalization pace, as CFO Birkemeyer said in Q3, "DME customers are taking longer than we initially expected to work through existing inventory," while still reiterating it is "ordering timing, not a change in patient demand or market leadership."

Quarter-over-Quarter Comparison

• Guidance posture shifted from Q2’s update to Q3’s reaffirmation and profitability lift, as CEO Dodd said in Q3, "we are maintaining our full year 2026 revenue guidance of $360 million to $366 million and raising our adjusted EBITDA guidance to $50 million to $52 million," compared with Q2, "we are updating our full year 2026 revenue guidance to a range of $360 million to $366 million" and "continue to expect to generate adjusted EBITDA of approximately $49 million to $51 million in 2026." (CEO, President & Director Dodd; Chief Financial Officer Birkemeyer)

• Airway clearance commentary became more conservative on timing in Q3, with CFO Birkemeyer stating, "we now expect full year revenue to decline in the mid- to high single digits compared with our prior expectation of approximately flat," versus Q2’s expectation that purchasing would "beginning to normalize in the fourth quarter." (Chief Financial Officer Birkemeyer; CEO, President & Director Dodd)

• Strategic emphasis in Q3 added operating leadership and process focus, including CEO Dodd: "Steve Kiewiet, is joining Tactile Medical as Chief Operating Officer" and disclosure that "technology-enabled improvements have reduced average review time by approximately 50%," building on Q2’s broader references to “care navigation work” and “tech transformation.” (CEO, President & Director Dodd; Chief Financial Officer Birkemeyer)

Risks and Concerns

• "DME customers are taking longer than we initially expected to work through existing inventory as they transition to the next-generation AffloVest." (Chief Financial Officer Birkemeyer)

• "Our total revenue range mainly reflects the timing of lymphedema referrals converting to shipments in the fourth quarter, our seasonally largest quarter." (Chief Financial Officer Birkemeyer)

• "We are encouraged that LymphaTech is currently in use and generating revenue at leading academic medical centers, even ahead of an established reimbursement pathway." (CEO, President & Director Dodd)

Final Takeaway

Management framed Q3 as continued lymphedema-driven growth with ongoing gross margin expansion, while describing airway clearance as a timing issue tied to DME inventory transition that is taking longer than previously expected. The company maintained full-year 2026 revenue guidance of $360 million to $366 million and raised adjusted EBITDA guidance to $50 million to $52 million, while outlining product and execution milestones that extend into 2027 and beyond, including a targeted Flexitouch Pro launch in the second half of 2027 and the February 2027 final review timing for a Category III CPT code for LymphaTech.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.